Literature DB >> 31871224

Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.

Ming-Yue Jiang1, Zeni Wu1, Tingyuan Li1,2, Lulu Yu1,3, Shao-Kai Zhang4, Xun Zhang5, Pengpeng Qu6, Peisong Sun6, Ming-Rong Xi7, Xin Liu1,8, Guangdong Liao7, Lixin Sun9, Yongzhen Zhang10, Wen Chen11, You-Lin Qiao11.   

Abstract

Women with positive high-risk human papillomavirus (hrHPV) need efficient triage testing to determine colposcopy referrals. Triage strategies of combining p16/Ki-67 with extended HPV genotyping were evaluated in this study. In total, 899 women attending cervical cancer screening program and 858 women referred to colposcopy from five hospitals were recruited. All the participants were tested by HPV assays and p16/Ki-67 dual staining. Colposcopy and biopsy were performed on women with any abnormal results. HPV genotypes were divided into four strata (HPV16/18, HPV31/33/58/52, HPV45/59/56/66, and HPV51/39/68/35) according to their risks for cervical intraepithelial neoplasia grade 3 or worse (CIN3+). The positive rates of four genotype strata among CIN3+ women were 3.47% (HPV51/39/68/35), 7.73% (HPV45/59/56/66), 14.7% (HPV31/33/58/52), and 78.1% (HPV16/18), respectively (P trend < 0.001). The positive rates of p16/Ki-67 increased with the elevation of HPV risk hierarchical from 65.0% in HPV51/39/68/35-positive women to 88.0% in HPV16/18-positive women (P trend < 0.001). p16/Ki-67 was an effective method for risk stratification of CIN2+ among HPV31/33/58/52- and HPV45/59/56/66-positive women [HPV31/33/58/52: OR for dual stain+ (ORDS+) of 26.7 (16.8-42.4) and OR for dual stain- (ORDS-) of 3.87(1.89-7.91); HPV45/59/56/66: ORDS+ of 10.3(5.05-21.0) and ORDS- of 1.27(0.38-4.26)]. The combination of HPV16/18 genotyping and p16/Ki-67 triage of HPV31/33/58/52/45/59/56/66-positive women resulted in a lower referral rate (40.1% vs. 41.3%; P < 0.001) as compared with triage of 12 other HPV-positive women with p16/Ki-67, although sensitivity and specificity levels for these two strategies were identical. Combining HPV extended genotyping and p16/Ki-67 can be considered as a promising strategy for cervical cancer screening and triage. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31871224     DOI: 10.1158/1940-6207.CAPR-19-0144

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  3 in total

1.  Novel concepts in cervical cancer screening: a comparison of VIA, HPV DNA test and p16INK4a/Ki-67 dual stain cytology in Western Kenya.

Authors:  Elkanah Omenge Orang'o; Edwin Were; Oliver Rode; Kapten Muthoka; Michael Byczkowski; Heike Sartor; Davy Vanden Broeck; Dietmar Schmidt; Miriam Reuschenbach; Magnus von Knebel Doeberitz; Hermann Bussmann
Journal:  Infect Agent Cancer       Date:  2020-10-02       Impact factor: 2.965

2.  Clinical impact of p16 positivity in nasopharyngeal carcinoma.

Authors:  Yuri Shimizu; Naoya Murakami; Taisuke Mori; Kana Takahashi; Yuko Kubo; Seiichi Yoshimoto; Yoshitaka Honma; Satoshi Nakamura; Hiroyuki Okamoto; Kotaro Iijima; Ayaka Takahashi; Tomoya Kaneda; Tairo Kashihara; Koji Inaba; Kae Okuma; Yuko Nakayama; Hiroshi Igaki; Jun Itami
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-06-14

3.  The Association of Molecular Biomarkers in the Diagnosis of Cervical Pre-Cancer and Cancer and Risk Factors in Senegalese.

Authors:  Dominique Diouf; Gora Diop; Cheikh Fall; Souleymane Sarr; Cheikh Ahmadou Tidian Diarra; Aminata Issa Ngom; Sidy Ka; Seynabou Lo; Oumar Faye; Ahmadou Dem
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.